trending Market Intelligence /marketintelligence/en/news-insights/trending/48cqCDAktha0B20h_yFBRw2 content esgSubNav
In This List

Indivior submits US FDA application for opioid-addiction treatment

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


Indivior submits US FDA application for opioid-addiction treatment

Indivior PLC submitted a new drug application to the U.S. FDA for its product candidate, RBP-6000, following a successful phase 3 study.

RBP-6000 is an investigational, once-monthly injectable form of buprenorphine to treat moderate to severe opioid use disorder.